MX394495B - Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo - Google Patents
Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismoInfo
- Publication number
- MX394495B MX394495B MX2020008488A MX2020008488A MX394495B MX 394495 B MX394495 B MX 394495B MX 2020008488 A MX2020008488 A MX 2020008488A MX 2020008488 A MX2020008488 A MX 2020008488A MX 394495 B MX394495 B MX 394495B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- method therefor
- crystal form
- oxopicolinamide
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Se proporcionan una forma cristalina de un derivado de oxopicolinamida y un método de preparación de la misma. En particular, se proporcionan formas cristalinas A, B, C, D, E y F de un compuesto como se muestra en la fórmula (I) y un método de preparación de las mismas. Las formas cristalinas A, B, C, D, E y F del compuesto de fórmula (I) obtenido en la presente descripción tienen buena estabilidad cristalina y estabilidad química, y se puede usar mejor en el tratamiento clínico.(VER FORMULA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810163529 | 2018-02-27 | ||
| PCT/CN2019/076132 WO2019165951A1 (zh) | 2018-02-27 | 2019-02-26 | 一种氧代吡啶酰胺类衍生物的晶型及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020008488A MX2020008488A (es) | 2022-08-04 |
| MX394495B true MX394495B (es) | 2025-03-24 |
Family
ID=67804814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008488A MX394495B (es) | 2018-02-27 | 2019-02-26 | Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11299462B2 (es) |
| EP (1) | EP3741746A4 (es) |
| JP (1) | JP2021514944A (es) |
| KR (1) | KR20200127196A (es) |
| CN (1) | CN111094241B (es) |
| AU (1) | AU2019227332A1 (es) |
| BR (1) | BR112020016856A2 (es) |
| CA (1) | CA3091528A1 (es) |
| MX (1) | MX394495B (es) |
| RU (1) | RU2020125154A (es) |
| TW (1) | TWI802654B (es) |
| UA (1) | UA126251C2 (es) |
| WO (1) | WO2019165951A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4036087A4 (en) * | 2019-09-27 | 2023-09-20 | Shenzhen Salubris Pharmaceuticals Co. Ltd | FXA INHIBITORS AND METHODS OF PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF |
| WO2023208169A1 (zh) * | 2022-04-29 | 2023-11-02 | 江苏恒瑞医药股份有限公司 | 一种凝血XIa抑制剂的离子液体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| WO2013093484A1 (en) | 2011-12-21 | 2013-06-27 | Ono Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
| US9809545B2 (en) * | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| WO2015063093A1 (de) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| WO2015120777A1 (zh) * | 2014-02-14 | 2015-08-20 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
| CN105658641B (zh) * | 2014-07-25 | 2018-04-17 | 江苏恒瑞医药股份有限公司 | 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用 |
| JP6517925B2 (ja) * | 2014-09-24 | 2019-05-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたオキソピリジン誘導体 |
| WO2016046156A1 (de) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
-
2019
- 2019-02-26 US US16/971,352 patent/US11299462B2/en not_active Expired - Fee Related
- 2019-02-26 MX MX2020008488A patent/MX394495B/es unknown
- 2019-02-26 WO PCT/CN2019/076132 patent/WO2019165951A1/zh not_active Ceased
- 2019-02-26 BR BR112020016856-4A patent/BR112020016856A2/pt not_active IP Right Cessation
- 2019-02-26 CN CN201980004501.8A patent/CN111094241B/zh active Active
- 2019-02-26 EP EP19761563.6A patent/EP3741746A4/en not_active Withdrawn
- 2019-02-26 JP JP2020542936A patent/JP2021514944A/ja active Pending
- 2019-02-26 AU AU2019227332A patent/AU2019227332A1/en not_active Abandoned
- 2019-02-26 KR KR1020207026713A patent/KR20200127196A/ko not_active Withdrawn
- 2019-02-26 CA CA3091528A patent/CA3091528A1/en active Pending
- 2019-02-26 TW TW108106509A patent/TWI802654B/zh active
- 2019-02-26 UA UAA202005137A patent/UA126251C2/uk unknown
- 2019-02-26 RU RU2020125154A patent/RU2020125154A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019227332A1 (en) | 2020-08-27 |
| UA126251C2 (uk) | 2022-09-07 |
| US20200385353A1 (en) | 2020-12-10 |
| KR20200127196A (ko) | 2020-11-10 |
| EP3741746A4 (en) | 2020-12-16 |
| WO2019165951A1 (zh) | 2019-09-06 |
| US11299462B2 (en) | 2022-04-12 |
| MX2020008488A (es) | 2022-08-04 |
| TW201936580A (zh) | 2019-09-16 |
| RU2020125154A (ru) | 2022-03-28 |
| CA3091528A1 (en) | 2019-09-06 |
| EP3741746A1 (en) | 2020-11-25 |
| TWI802654B (zh) | 2023-05-21 |
| JP2021514944A (ja) | 2021-06-17 |
| CN111094241B (zh) | 2022-06-21 |
| CN111094241A (zh) | 2020-05-01 |
| BR112020016856A2 (pt) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4585268A3 (en) | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same | |
| AU2016237099B2 (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
| MY188447A (en) | Indazole compounds as fger kinase inhibitor, preparation and use thereof | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| AU2015352440B2 (en) | Compounds | |
| JOP20190254A1 (ar) | مركبات مضادة للأورام | |
| MX2018009633A (es) | Inhibidor de indoleamina-2,3-dioxigenasa (ido). | |
| GEP20207161B (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX2021015102A (es) | Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r). | |
| MX2016011898A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
| MX395263B (es) | Forma cristalina de base libre de lorlatinib | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| MX2024009894A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| EP4663247A3 (en) | Formulations/compositions comprising a btk inhibitor | |
| EA201992360A1 (ru) | Кристаллические формы (s)-афоксоланера | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| EP4364741A3 (en) | Polymorphic form of tg02 | |
| WO2018125880A8 (en) | Nrf2 activator | |
| MX2016016148A (es) | Preparacion de rocuronio con estabilidad mejorada. | |
| ZA201805790B (en) | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof | |
| BR112017012646A2 (pt) | Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas | |
| EA201992302A1 (ru) | Соединения, используемые в качестве ингибиторов alcat1 | |
| MY198916A (en) | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof |